Variable absorption on AndroGel (testosterone topical): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence of sub-therapeutic levels on starting dose: ~29% of subjects in the AndroGel 1% phase III trial failed to achieve T ≥300 ng/dL at day 30 on 5 g/day
• Incidence of supra-therapeutic levels: ~5-9% exceeded 1000 ng/dL on 5 g/day; up to 15% on 10 g/day
• Typical timeline to detectable variability: First steady-state serum level is measurable at day 14-30; inter-individual spread is apparent from the first monitoring draw
• First-line management: Application technique correction (dry, intact skin; consistent site rotation), followed by dose titration per label (5 g to 7.5 g or 10 g)
• When to escalate: Persistent sub-therapeutic levels after technique correction and one dose step up; or any level >1050 ng/dL on repeat testing
• When to discontinue: Inability to maintain T 300-1000 ng/dL range across two titration attempts; significant secondary transfer risk that cannot be mitigated

Why absorption varies this much in the first place

AndroGel delivers testosterone transdermally across the stratum corneum, the outermost skin layer. The drug relies entirely on passive diffusion, meaning that anything affecting that barrier directly changes how much testosterone actually reaches systemic circulation. Skin thickness varies by anatomical site, age, and hydration state. Scrotal skin, for example, absorbs testosterone roughly five times more efficiently than the upper arm or shoulder, which is why application site selection matters far more than patients are typically told.

The formulation uses an ethanol-based gel that briefly permeabilizes the stratum corneum, deposits testosterone into a skin reservoir, and allows gradual systemic entry over 24 hours. Because the reservoir itself varies in depth and lipid composition between individuals, two men applying the same 5 g dose to the same anatomical location can produce peak serum levels that differ by 200-400 ng/dL. This is not a product defect. It reflects the fundamental pharmacokinetics of transdermal drug delivery.

Adipose tissue complicates things further. Testosterone is lipophilic and partitions into fat, so men with higher body fat tend to show blunted peak levels and prolonged low-level release. This pattern contributes to the observation that obese hypogonadal men often require larger doses to sustain mid-normal trough levels, and it explains why weight loss can sometimes shift a previously stable patient out of therapeutic range.

What the trial data actually show

The key phase III registration trial for AndroGel 1% (the Solvay-sponsored 180-day multicenter study published in 2000, subsequently cited in the FDA prescribing information) enrolled 227 hypogonadal men randomized to 5 g/day, 10 g/day, or placebo. At day 30 to 66% of the 5 g group achieved T within the eugonadal range of 300-1000 ng/dL. That means approximately 34% either fell short or exceeded the ceiling on the starting dose, without any technique error on their part.

By day 90 with permitted titration, eugonadal attainment reached 87% in the 5 g arm and 77% in the 10 g arm (the higher-dose group had more supra-therapeutic values requiring downward adjustment). Those numbers sound reassuring until you consider that 13% of patients on the most common starting dose still had not reached target range by three months, and virtually all of the published trial participants were motivated to apply the gel correctly in a supervised research setting. Real-world adherence and technique tend to be lower.

A 2014 observational study by Baillargeon et al. examining testosterone monitoring patterns in a large U.S. managed care database found that only about 40% of men on testosterone gel had a follow-up serum level drawn within the recommended 14-90 day post-initiation window. Among those who did get monitored, dose adjustments were required in roughly 35-40% of cases. The gap between trial-setting outcomes and real-world outcomes is real and clinically meaningful.

Severity distribution: who ends up at which extreme

Sub-therapeutic absorption (T persistently <300 ng/dL despite correct application) is the more common failure mode. It tends to cluster in men who:

• Apply gel to areas with thicker, less permeable skin (inner wrist, lower abdomen versus recommended shoulder or upper arm)
• Have significant truncal obesity with a BMI above 30
• Apply gel immediately after toweling off from a shower, when transient skin vasodilation may accelerate evaporation of the ethanol carrier before absorption is complete
• Wash the application site within six hours, which removes testosterone before depot formation is complete

Supra-therapeutic absorption (T >1050 ng/dL) is less common on 5 g/day but becomes clinically relevant at 10 g/day. When it occurs, it tends to produce erythrocytosis, elevated hematocrit, acne, and in some cases sleep-disruption from elevated androgen activity. The Endocrine Society clinical practice guideline on testosterone therapy recommends reducing dose or switching formulation if T exceeds 1050 ng/dL on two consecutive measurements.

A small subset of men, estimated at 5-10% in clinical practice series, show extreme inter-day variability where a single patient's levels can swing by 300-500 ng/dL between measurements taken under apparently identical conditions. This pattern often reflects inconsistent skin preparation rather than any intrinsic biological instability, but it can also indicate a need to switch to an injectable or pellet formulation with more predictable pharmacokinetics.

Application technique: where most correctable variability originates

Most absorption problems that reach a prescriber's attention are at least partially technique-driven. The AndroGel prescribing information specifies shoulders, upper arms, and abdomen as approved application sites. Each site has different epidermal thickness and vascularity.

The practical correction checklist is short:

1. Apply to clean, dry skin at the same time each day (morning is preferred to align with endogenous diurnal peaks and to allow measurement of a consistent trough-to-peak window for monitoring)
2. Allow the gel to air-dry completely before dressing, at minimum two minutes
3. Do not shower, swim, or wash the area for at least two hours post-application, with six hours providing better depot formation
4. Rotate between left and right shoulder or upper arm on alternating days to prevent local skin changes that reduce permeability over time
5. Avoid applying to broken, sunburned, or recently shaved skin, all of which alter barrier function unpredictably

A 2011 review by Wang et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that application to the inner thigh produced meaningfully higher serum levels than shoulder application in a crossover design, which explains why some patients who drift supra-therapeutic on a stable dose have quietly changed where they apply the gel.

Monitoring intervals and dose titration: the clinical workflow

The recommended monitoring sequence is a serum total testosterone drawn 14 days after starting or after each dose change, with the blood draw timed two hours post-application to approximate the peak, or alternatively at the trough (immediately before the next day's dose). Labs collected at inconsistent times relative to application produce uninterpretable results and drive unnecessary titration errors.

If total T at day 14-30 is below 300 ng/dL and technique has been verified, the label supports increasing from 5 g to 7.5 g or 10 g daily. If levels remain sub-therapeutic after one dose step up and confirmed correct technique, the probability of adequate long-term control with gel is low and a formulation switch to injectable testosterone cypionate or enanthate, or to a nasal gel such as Natesto, is reasonable to discuss.

Hematocrit should be checked at baseline and at three months, given that erythrocytosis is a class effect of testosterone therapy regardless of formulation, and supra-therapeutic absorption accelerates its onset. The Endocrine Society guideline flags hematocrit >54% as a threshold for dose reduction or phlebotomy consideration, independent of symptom status.

Secondary transfer: an underappreciated contributor to "variable" levels

One absorber who gets consistent results can still produce variable downstream effects if secondary transfer occurs to a partner or child. FDA safety communications issued in 2009 flagged virilization cases in pediatric contacts. While this does not affect the treated patient's own levels, accidental transfer can expose household members to clinically meaningful testosterone doses from residual gel on skin or clothing.

The practical mitigation is straightforward: cover the application site with clothing after the gel dries, and wash hands thoroughly after application. Partners should avoid skin-to-skin contact with the application site until the patient has showered.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology and Metabolism. 2000;85(8):2839-2853. https://pubmed.ncbi.nlm.nih.gov/10946892/
• AbbVie. AndroGel (testosterone gel) 1% and 1.62% prescribing information. U.S. Food and Drug Administration. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s034lbl.pdf
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
• Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Internal Medicine. 2013;173(15):1465-1466. https://pubmed.ncbi.nlm.nih.gov/24256378/
• Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Handelsman DJ. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Journal of Clinical Endocrinology and Metabolism. 2011;96(5):1245-1251. https://pubmed.ncbi.nlm.nih.gov/21646371/
• U.S. Food and Drug Administration. FDA drug safety communication: FDA evaluating risk of cardiovascular events and testosterone products. 2009. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluating-risk-cardiovascular-events-and-testosterone-products
• Transdermal drug delivery: pharmacokinetics and clinical considerations. StatPearls. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK553147/